A B S T R A C T The characteristics of cyclophosphamideinduced suppression of established cell-mediated immunity were studied in guinea pigs previously sensitized to tuberculin. Cyclophosphamide treatment for 5 days produced a dose-dependent peripheral lymphocytopenia and a disproportionately greater neutropenia which was particularly striking at high doses of 20 mg/kg per day (approximately 200 mg/m' per day). Lymphocytes remaining in the circulation of cyclophosphamidetreated animals showed a dose-dependent reduction of both in vitro proliferative and macrophage migration inhibitory factor responses to tuberculin compared to lymphocyte responses of controls. Proliferative responses to phytohemagglutinin and concanavalin A were not significantly suppressed. Additional studies showed that cyclophosphamide suppressed the proliferative and migration inhibitory factor responses to tuberculin of lymph node and splenic as well as circulating lymphocyte populations. These studies showed that relatively short-term cyclophosphamide administration produced immunosuppression by quantitative as well as qualitative changes in lymphocyte populations. Significant suppression of lymphocyte function, however, was achieved only with doses of cyclophosphamide which also produced a severe neutropenia.
INTRODUCTION
Striking alterations of host defense mechanisms during the course of cyclophosphamide (CY)' therapy are wellRcceived for publication 2 December 1974 and in revised form 26 February 1975. 'Abbreviations used in this paper: CFA, complete Freund's adjuvant; Con A, concanavalin A; CY, cyclophosrecognized features of its use in clinical medicine. Although several tissues are potentially susceptible to the toxic effects of CY, the particular sensitivity of the lymphoid system in man and experimental animals has led to investigation of the use of CY in autoimmune and chronic inflammatory diseases. Dramatic results of short-term CY therapy have been obtained in experimental models of immunologically mediated diseases and in certain types of human diseases (1, 2) . However, clinical conditions requiring high dose and/or longterm therapy are fraught with considerable hazard due to concomitant suppression of host defense mechanisms (1, 3) . These complications occur, at least in part, because of our currently incomplete knowledge of the mechanism of action of CY beyond its general classification as an alkylating agent. For example, it is unclear whether CY-induced immunosuppression results from specific defects in lymphoid cell function or simply from induction of lethal effects leading to depletion of lymphoid cells. The ability of CY to affect nondividing, as well as rapidly dividing lymphocytes renders it a useful agent to alter preexisting immunocompetence (4) .
The present studies were undertaken to further characterize the nature of effective suppression by CY of established cell-mediated immune reactions. The guinea pig was used for study because in vitro correlates of cell-mediated immunity are technically and theoretically phamide; LNL, lymph node lymphocytes; MEM-S, Eagle's minimal essential medium, Spinner modification; MIF, migration inhibitory factor; PBL, peripheral blood lymphocytes; PEC, peritoneal exudate cells; PHA, phytohemagglutinin; PPD, purified protein derivative of tuberculin. well defined (5) , and animal studies offered the ability to study wider ranges of drug dosages compared to human studies. Thus, varying doses of CY were assessed for their effects on lymphocyte numbers, as well as function measured by in vitro proliferative responses and soluble mediator production.
METHODS
Immunization. Strain guinea pig serum at a final density of 1 X 106 cells/ml with various concentrations of antigen or mitogens as will be described in individual experiments. Lymphocytes were cultured as has previously been described (7) . Briefly, cell cultures were prepared in microtiter plates (Cooke Laboratory Products Div., Dynatech Laboratories, Inc., Alexandria, Va.). Quadruplicate wells, each containing 2 X 10l cells, were prepared for each antigen or mitogen concentration to be tested. PHA-and Con A-stimulated cultures consistently showed peak proliferative responses after 3 days of culture, while PPD responses peaked at 4 days. 18 h before harvesting, 0.4 ACi of tritiated thymidine (6.7 Ci/ mM, New England Nuclear, Boston, Mass.) was added to each well. The cells were collected from the wells onto Fiberglas filters using a semiautomated microharvesting device. The filters were washed with 10% trichloroacetic acid (TCA) and 95% ethanol, then placed in vials containing 10 Fig. 2 . There was a dose-dependent suppression of MIF responses, with differences in the low-dose CY (5 and 10 mg/kg) groups being apparent only at low concentrations of PPD, while 20 mg/kg of CY suppressed MIF responses at all concentrations of PPD. The possibility that disproportionately greater rates of cell death subsequent to initial preparation of the assays could explain the difference in MIF responses between CY and control groups was unlikely, since the numbers and viabilities of PBL from control and CY (20 mg/kg) groups cultured separately for 24 h were equivalent. Thus, although CY produces a significant, dose-dependent peripheral lymphocytopenia, it also reduces the functional capacity of those lymphocytes remaining in the circulation to produce MIF, a soluble mediator of cell-mediated reactions.
Effects of CY on antigen-and mitogen-induced proliferation of PBL. Aliquots of Hypaque-Ficoll preparations of PBL for MIF assay were simultaneously cultured in lymphocyte transformation assays. The proliferative response (Acpm), as a function of increasing concentrations of PPD, is shown in Fig. 3 for groups the absolute value of Acpm in both treated and control PBL showed marked day-to-day variability in PHA and Con A experiments, the data is expressed as follows: pairs of treated and control animals were simultaneously studied, and the Acpm generated by PBL from CY-treated animals was expressed as a percent of the Acpm generated by simultaneously assayed control PBL. Optimal proliferative responses for PHA and Con A were produced by 1.0 and 10 iAg/ml, respectively.
As shown in Table I (28) .
The present studies also demonstrate that CY can effectively suppress the production of a soluble mediator or lymphokine (MIF), a lymphocyte function which is not dependent on cellular division (29, 30 The relationship of the observations in the animal studies reported here to clinical situations will depend on further elucidation of the relationships of Cyclophosphamide Suppression of Cell-Mediated Immunity 69 changes in lymphocyte numbers and functions to therapeutic responses in various disease states. Recent studies have shown that the activity of certain diseases improved by CY is associated with a reduction of lymphocyte numbers, but not with a detectable depression of mitogen-induced lymphocyte proliferation (22, 23) . These studies, in conjunction with the findings of the present report, caution that the adequacy of immunosuppressive therapy with CY may not be safely monitored by tests of in vitro mitogen responses of lymphocytes, since doses of CY which suppress these lymphocyte functions may be associated with potential compromise of host defense mechanisms by increasing the risk of development of significant neutropenia.
